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Abstract
Background: Accurately quantifying the risk of osteoporotic fracture is important for directing appropriate clinical
interventions. While skeletal measures such as heel quantitative speed of sound (SOS) and dual-energy X-ray
absorptiometry bone mineral density are able to predict the risk of osteoporotic fracture, the utility of such
measurements is subject to the availability of equipment and human resources. Using data from 341,449 individuals
of white British ancestry, we previously developed a genome-wide polygenic risk score (PRS), called gSOS, that
captured 25.0% of the total variance in SOS. Here, we test whether gSOS can improve fracture risk prediction.
Methods: We examined the predictive power of gSOS in five genome-wide genotyped cohorts, including 90,172
individuals of European ancestry and 25,034 individuals of Asian ancestry. We calculated gSOS for each individual
and tested for the association between gSOS and incident major osteoporotic fracture and hip fracture. We tested
whether adding gSOS to the risk prediction models had added value over models using other commonly used
clinical risk factors.
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Results: A standard deviation decrease in gSOS was associated with an increased odds of incident major
osteoporotic fracture in populations of European ancestry, with odds ratios ranging from 1.35 to 1.46 in four
cohorts. It was also associated with a 1.26-fold (95% confidence interval (CI) 1.13–1.41) increased odds of incident
major osteoporotic fracture in the Asian population. We demonstrated that gSOS was more predictive of incident
major osteoporotic fracture (area under the receiver operating characteristic curve (AUROC) = 0.734; 95% CI 0.727–
0.740) and incident hip fracture (AUROC = 0.798; 95% CI 0.791–0.805) than most traditional clinical risk factors,
including prior fracture, use of corticosteroids, rheumatoid arthritis, and smoking. We also showed that adding gSOS
to the Fracture Risk Assessment Tool (FRAX) could refine the risk prediction with a positive net reclassification index
ranging from 0.024 to 0.072.
Conclusions: We generated and validated a PRS for SOS which was associated with the risk of fracture. This score
was more strongly associated with the risk of fracture than many clinical risk factors and provided an improvement
in risk prediction. gSOS should be explored as a tool to improve risk stratification to identify individuals at high risk
of fracture.
Background
Osteoporosis is among the most common diseases
worldwide and is characterized by a reduction in bone
mass and microarchitectural integrity, resulting in an in-
creased predisposition to fracture [1]. In the Western
world, between one third to one half of women will ex-
perience an osteoporotic fracture in their lifetime [2].
The burden of this disease will increase substantially as
our population ages, such that by the year 2040, the an-
nual incidence of hip fractures is expected to surpass
500,000 in the USA and the direct medical costs of sur-
gery for each hip fracture will exceed $65–68,000 USD
[3]. Given this impending financial and societal burden,
efforts to improve earlier detection of those at high risk
of fracture will enable more effective intervention
strategies.
Studies based on large cohorts have shown that
skeletal measures, such as quantitative ultrasound
speed of sound (SOS) and dual-energy X-ray absorpti-
ometry (DXA) bone mineral density (BMD), can pre-
dict the risk of osteoporotic fracture with a high
specificity but poor sensitivity [1, 4]. However, the
utility of such measurements is subject to the avail-
ability of equipment and human resources and, in
some jurisdictions, can be relatively expensive [5]. Ef-
fective risk stratification relying on other clinically
relevant risk factors is available. For example, the
Fracture Risk Assessment Tool (FRAX) has been de-
veloped to predict 10-year probabilities of major
osteoporotic fracture and hip fracture by integrating
multiple clinical risk factors [6]. Combining these
clinical risk factors with femoral neck BMD in the
FRAX score has become widely accepted as a method
to appropriately stratify individuals for therapy [7–10].
With the advent of large-scale genome-wide genotyped
cohort resources, such as UK Biobank, and emerging
computational algorithms, genomic prediction of com-
plex traits and diseases may improve disease prediction
accuracy and thus potential clinical utility [11, 12]. Both
BMD and SOS are clinically used to predict fracture risk
and are moderately correlated, with high heritability
(50–85%) [13]. This suggests that polygenic risk scores
could be developed for these skeletal measures [14, 15].
Polygenic risk scores could also be developed in the
field of osteoporosis to better identify individuals at risk
for fracture. In previous work, a genetic risk score in-
cluding 21 single nucleotide polymorphisms (SNPs) in
19 genes associated with osteoporosis-related traits was
moderately associated with nonvertebral fracture risk in
Korean postmenopausal women and might slightly im-
prove clinical osteoporotic risk factor-based fracture risk
prediction [16]. Another genetic risk score based on 62
SNPs associated with femur neck or lumbar spine BMD
accounted for approximately 2% of the variance in BMD
and conferred a hazard ratio of 1.20 for incident fragility
fracture per one standard deviation increase [17]. A
similar score summarizing 63 BMD loci was associated
with BMD during childhood and was moderately associ-
ated with fracture risk in adulthood [18, 19]. Moreover,
a genetic risk score leveraging 979 SNPs in 74
osteoporosis-susceptibility genes was developed in
Japanese women and could identify individuals having
prevalent vertebral fractures with an area under the re-
ceiver operating characteristic curve (AUROC) of 0.788
[20]. More recently, using 1103 independent SNPs asso-
ciated with estimated BMD (eBMD) of the heel, a poly-
genic risk score for eBMD has been shown to be able to
predict site-specific fractures [21]. However, due to the
polygenic nature of these skeletal traits and the usually
limited study sample sizes, existing genetic risk scores
may not be able to sufficiently capture the underlying
genetic predisposition towards fracture and therefore
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may not provide optimal predictive performance. Conse-
quently, the clinical utility of genetic risk scores in frac-
ture risk prediction, especially among the elderly
population, has been questioned [22].
Using data from the UK Biobank, we have previously
developed a genome-wide polygenic risk score for SOS,
called genomic SOS (gSOS), that captures 25.0% of the
total variance in SOS [23]. This largely exceeded an
existing polygenic risk score which explained 17.2% of
the total variance and achieved an AUROC of 0.570 for
identifying individuals with any type of fracture [24]. In
comparison, FRAX clinical risk factors, age, sex, and
BMI together explain 4.0% (95% confidence interval (CI)
3.7–4.2%) of the variance in SOS [23]. gSOS has been
shown to be independent of other commonly used clin-
ical risk factors and significantly associated with fracture
risk [23]. However, the clinical utility of gSOS to predict
osteoporotic fracture risk remains largely unexplored.
Here, we have assessed the predictive performance of
gSOS in 90,172 individuals of European ancestry in four
study cohorts, the UK Biobank [25], the United States-
based Osteoporotic Fractures in Men Study (MrOS US)
[26], the Sweden-based Osteoporotic Fractures in Men
Study (MrOS Sweden) [27], and the Study of Osteopor-
otic Fractures (SOF) [28, 29]. We further investigated
whether combining gSOS with FRAX could better iden-
tify individuals at high risk of osteoporotic fracture. We
also tested the generalizability of gSOS to a non-
European population consisting of 25,034 individuals,
using data from the China Kadoorie Biobank (CKB)
study [30]. Data from this study have been presented at
the American Society for Bone and Mineral Research
2020 Annual Meeting [31].
Methods
Study cohorts
This study included five cohorts: the UK Biobank [25],
the MrOS US [26], the MrOS Sweden [27], the SOF
[28], and the CKB [30].
The UK Biobank comprises more than 500,000 partici-
pants who were recruited at multiple assessment centers
in the UK and were enrolled between 2006 and 2010 at
ages ranging from 40 to 69 years. Compared to a general
population, the UK Biobank has been reported to be
healthier, less obese, and less likely to smoke and drink
alcohol [32]. Participants of the UK Biobank were
genome-wide genotyped using Affymetrix arrays, and
their genotypes were imputed to the Haplotype Refer-
ence Consortium (HRC) reference panel [25, 33]. Site-
specific major osteoporotic fractures were defined based
on ICD10 codes of primary diagnoses (M8002, M8003,
M8005, M8008, M8082, M8083, M8085, M8088, S220,
S320, S422, S423, S424, S520, S521, S522, S523, S525,
S526, S529, S720, S721, and S722) and self-reported
medical history. Since the exact cause of fracture was
not identifiable, these identified events may include trau-
matic fractures. Fracture risk factors were those captured
at the baseline visit, and incident fractures were defined
to be those occurring after the baseline visit.
The MrOS is an international multicenter longitudinal
study comprised of elderly men [27]. The MrOS US
cohort recruited 5995 men aged ≥ 65 years at multiple
assessment centers in the USA between 2000 and 2002
[26]. Baseline examinations were conducted upon re-
cruitment followed by a more extensive questionnaire
after 2–2.5 years of follow-up. After a mean follow-up of
4.5 years, a second clinic visit was completed. Tri-annual
questionnaires inquiring about the occurrence of inci-
dent falls, fractures, and fracture risk factors were col-
lected during the intervening period. In this cohort, 11%
of the participants were visible minorities. Among these
5995 men, 5130 were genotyped. After overlaying the
first two genetic principal components with those from
the 1000 Genomes Project [34], 4663 men of a genetic-
ally determined European ancestry were included in this
study. Their genotypes were imputed to the HRC refer-
ence panel. The MrOS Sweden cohort recruited 3014
men aged 69 to 81 years in three Swedish cities between
2001 and 2004 [35]. After baseline examinations, partici-
pants were followed for up to 10 years after the baseline
examination. Fracture evaluation was done by searching
digital X-ray archives and matching them with MrOS
Sweden participants using unique personal identification
number, which all Swedish citizens have. Among these
3014 men, 1880 were genotyped and included in this
study. Their genotypes were imputed to the HRC refer-
ence panel.
The SOF cohort recruited 9704 women at four assess-
ment centers in the USA who were aged ≥ 65 years at
enrollment between 1986 and 1988 [28]. Falls and
fractures were monitored every 4 months. After baseline
examinations, follow-up examinations took place ap-
proximately every 2 years during a mean follow-up of
14.5 years. Among these 9704 women, 3625 were geno-
typed, and 3615 women with a genetically determined
European ancestry with reference to the 1000 Genomes
Project [34] were included in this study. Their genotypes
were also imputed to the HRC reference panel.
To be eligible for the MrOS US, the MrOS Sweden, or
the SOF cohorts, participants were required to (1) be
able to walk without the assistance of another, (2) not
have had bilateral hip replacements, and (3) be able to
provide self-reported data [26–28]. All reported fractures
after baseline were confirmed by a physician review of
the radiology report.
The CKB cohort recruited more than 500,000 adults
aged between 30 and 79 years, from 2004 to 2008 in 10
survey sites in China [30]. After the baseline survey,
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long-term follow-up was conducted by accessing elec-
tronic records of mortality registries, morbidity regis-
tries, and all hospitalized events and procedures that are
available for 98% of the participants covered by the
nation-wide health insurance system. SOS and incident
fracture were collected for 25,034 participants during
the second survey of the CKB between 2013 and 2014.
These participants were genotyped, and their genotypes
were imputed to a 1000 Genomes Project-based refer-
ence panel for East Asian populations [34].
Each study was approved by the institutional review
boards of participating institutions and, all participants
provided informed consent to respective studies.
Risk factor measurement
Clinically relevant risk factors were measured at the
baseline visit for these cohorts, including FRAX clinical
risk factors, such as age, sex, BMI (in the unit of kg/m2),
prior fractures (hip fractures and other osteoporotic
fractures), smoking, glucocorticoid use, rheumatoid arth-
ritis, and femoral neck BMD based on DXA scan. Diag-
nosis of secondary causes of osteoporosis (type 1
diabetes, osteogenesis imperfecta in adults, untreated
long-standing hyperthyroidism, hypogonadism or pre-
mature menopause, chronic malnutrition, or malabsorp-
tion and chronic liver disease) was available only in the
UK Biobank. Parental history of fracture, at-risk drinking
(≥ 3 units per day), and self-reported falls (a risk factor
independent of FRAX probability [36]) based on inter-
views or questionnaires were available in the MrOS US,
the MrOS Sweden, and the SOF cohorts. Cohorts with
missing risk factor measurements were considered free
of the corresponding risk factors for the derivation of
FRAX probability, as suggested by the FRAX model
(https://www.sheffield.ac.uk/FRAX/faq.aspx).
Development of a polygenic risk score
As described previously [23], we developed a polygenic
risk score using a statistical learning approach to predict
SOS, a risk factor for osteoporotic fracture in the UK
Biobank. The polygenic risk score for FRAX is referred
to here as “gSOS.”
There were 426,811 participants in the UK Biobank of
white British ancestry who had measured SOS and had
undergone genome-wide genotyping. We first assigned
these individuals to a training dataset (N = 341,449, 80%
of the total cohort), a model selection dataset (N = 5335,
1.25% of the total cohort), and a test dataset (N = 80,014,
18.75% of the total cohort). All 4717 individuals with
femoral neck BMD measurements were assigned to the
test dataset in order to compare the fracture predictive
performance of gSOS with BMD. We performed a
genome-wide association study on the training dataset
using a linear mixed model adjusting for age, sex,
assessment center, genotyping array, and the top 20 gen-
etic principal components. We next performed a series
of least absolute shrinkage and selection operator
(LASSO) regressions [37] in the training dataset using
SOS as an outcome and SNPs as predictors, applying
different p value thresholds (p ≤ 5 × 10−3, p ≤ 5 × 10−4,
p ≤ 5 × 10−5, p ≤ 5 × 10−6, p ≤ 5 × 10−7, and p ≤ 5 × 10−8)
after removing SNPs demonstrating linkage disequilib-
rium (r2 > 0.05) with other SNPs. Each LASSO regres-
sion model thus yielded a polygenic risk score with
tuned coefficients associated with different subsets of
SNPs. We selected the best-performing model as that
with the highest proportion of variance explained in the
model selection dataset (Additional file 1: Table S1).
This model included 21,717 activated SNPs with a p
value ≤ 5 × 10−4 and was able to explain 23.18% (95% CI
22.66%–23.69%) of the total variance in the test dataset
[23]. Since all SNPs employed in the optimized poly-
genic risk score were present in all European ancestry
cohorts under investigation, we obtained a genetically
predicted SOS (gSOS) for each individual in the UK Bio-
bank test dataset as well as the other three cohorts. We
did not perform downstream analyses on the UK Bio-
bank training and model selection datasets, since these
datasets were used to generate and select gSOS, respect-
ively, and could therefore be prone to biased estimates
due to model over-fitting.
Because the genotypes of CKB participants were im-
puted to a different reference panel, only 13,848 acti-
vated SNPs were available in the CKB. Using these
available SNPs, we derived a gSOS estimate for each
CKB participant. Differences in minor allele frequencies
between the CKB and the UK Biobank are summarized
in Additional file 1: Fig. S1.
Derivation of FRAX-based risk scores
The country-specific FRAX tool (https://www.sheffield.
ac.uk/FRAX/) incorporating clinically relevant risk
factors was used to calculate the 10-year probability of
experiencing a major osteoporotic fracture or a hip frac-
ture [6]. For individuals whose femoral neck BMD was
available, a FRAX score including BMD was also calcu-
lated using this algorithm.
We also developed a clinical risk factor plus gSOS-
based FRAX (FRAX-gSOS). The largest meta-analysis of
osteoporosis cohorts to date, which did not include the
UK Biobank, estimated that one standard deviation de-
crease in SOS was associated with 1.42-fold increased
odds of experiencing major osteoporotic fracture [4].
Therefore, to generate a gSOS-adjusted FRAX score for
major osteoporotic fracture, we first converted the
FRAX algorithm-derived fracture probabilities to odds of
fracture. We divided the odds by 1.42 to the power of
standardized gSOS, such that an individual with a
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standardized gSOS of 1 would have a 1.42-fold de-
creased odds; an individual with a standardized gSOS of
− 1 would have a 1.42-fold increased odds. The adjusted
odds were then converted back to fracture probabilities.
For hip fractures, the same transformation was per-
formed, except that the increase in risk per standard de-
viation decrease in SOS was previously demonstrated to
be 1.80-fold [4].
Thus, for each individual, three FRAX scores were
generated: a clinical risk factor-based FRAX (FRAX-
CRF), a clinical risk factor plus BMD-based FRAX
(FRAX-BMD), and a FRAX-gSOS. This allowed a direct
comparison of the predictive accuracy of each of these
three methods.
Due to the missingness of several FRAX clinical risk
factors in the CKB cohort (Table 1), we did not generate
FRAX scores for CKB participants. Analyses were thus
restricted to testing the association (described below) be-
tween gSOS and incident major osteoporotic fracture or
hip fracture risk adjusted for age and sex in the CKB co-
hort. We then compared the effect size of gSOS with
those obtained in European populations based on the
other cohorts.
Statistical analysis in European ancestry-based cohorts
We first standardized gSOS scores for each cohort sep-
arately to have a mean of zero and a standard deviation
of one. This enables a more standardized comparison of
effects across cohorts. Since risk predictors are more
useful if they are independent of known risk factors, we
assessed linear correlations between gSOS and clinically
relevant risk factors of fracture using the Pearson correl-
ation coefficient. We next quantified incident major
osteoporotic fractures and binomial proportion CIs
among individuals grouped with respect to different
quantile ranges of gSOS: ≤ 1%, 1–5%, 5–20%, 20–40%,
40–60%, 60–80%, 80–95%, 95–99%, and > 99%.
We tested the association between the risk of incident
major osteoporotic fracture and gSOS as well as other
clinically relevant risk factors using logistic regression
adjusted for age and sex. We also tested the association
between the risk of incident major osteoporotic fracture
and each of the three FRAX scores using logistic regres-
sion without adjusting for age and sex since they are in-
cluded in the FRAX algorithm. Model comparison was
performed by the likelihood ratio test. We assessed the
predictive performance of each of the three FRAX scores
using the AUROC or the area under the precision-recall
curve (AUPRC) for major osteoporotic fractures.
AUROC and CIs were computed using the R package
“pROC” version 1.15.3 [38]. DeLong’s test was per-
formed to compare AUROC [39]. AUPRC and boot-
strapped CIs were computed using the R package
“PRROC” version 1.3.1 [40].
Further, we evaluated the cumulative incidence of
major osteoporotic fracture in the MrOS US and SOF
cohorts separately by Kaplan-Meier estimates, censored
at 90 years. These studies were selected because of their
longer length of follow-up. We also assessed the
cumulative risk of incident major osteoporotic fracture
associated with gSOS, FRAX clinical risk factors, and
FRAX-based scores by Cox proportional hazards regres-
sion using age at the time of fracture as the time scale.
Timing of fracture was not available for other cohorts.
The MrOS US and SOF cohorts were combined in the
Cox models which were then sex-stratified. We assessed
the predictive performance of each model using C-index
(a generalization of the AUROC considering censored
data in Cox models). Survival analyses were performed
using the R package “rms” version 5.1-3.1 [41, 42]. C-
indices and 95% CIs were computed using the R package
“Hmisc” version 4.2-0 [41, 43]. The above analyses were
repeated for incident hip fracture.
Lastly, we examined whether a FRAX-gSOS score can
improve clinical screening by net reclassification index
(NRI) and integrated discrimination index (IDI) [44].
The NRI measures how well a new predictive model cor-
rectly categorizes individuals into their corresponding
groups, while the IDI quantifies changes in the average
discriminative power. We compared the gSOS-FRAX
score to the CRF-FRAX score. The clinical cutoff was
set at 20% and 3% (above which pharmacological treat-
ment is recommended by the National Osteoporosis
Foundation [45]) respectively for predicted 10-year
major osteoporotic fracture risk and hip fracture risk.
NRIs and IDIs were computed using the R package “Pre-
dictABEL” version 1.2-2 [46].
Results
Study characteristics
Demographic features, incidence of major osteoporotic
fracture and hip fracture, prevalence of each FRAX risk
factor, and FRAX-based scores are summarized for each
of the five cohorts used in Table 1. Among the European
ancestry cohorts, the MrOS US, the MrOS Sweden, and
the SOF cohorts comprised elderly men or women,
while individuals in the UK Biobank test dataset were
comparatively younger with lower FRAX scores. Like the
UK Biobank, the CKB cohort was also younger and prior
fracture, an age-related risk factor, was less prevalent in
these two cohorts. In contrast, the SOF cohort,
comprised entirely of elderly women, had the highest
prevalence of prior fracture, corticosteroids use, and
rheumatoid arthritis, as well as the highest average
FRAX-based scores. Thus, the five cohorts analyzed pro-
vide different populations within which to evaluate frac-
ture prediction performance, providing a more thorough
assessment of its generalizability.
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Table 1 Study characteristics
Characteristic UK Biobank test dataset MrOS US MrOS Sweden SOF CKB
Mean/N Missing/N Mean/N Missing/N Mean/N Missing/N Mean/N Missing/N Mean/N Missing/N
Sample size 80,014 4663 1880 3615 25,034
Baseline age (SD) 56.8 (8.0) 74.0 (6.0) 75.4 (3.2) 71.5 (5.3) 53.7 (11.0)
Women (%) 43,723 (54.6) 0 0 3615 (100) 14,334 (57.3)
Baseline BMI (SD) 27.3 (4.7) 4 27.4 (3.8) 1 26.4 (3.5) 26.7 (4.6) 23.7 (3.5)
Prior fracture (%) 8008 (10.0) 21 1087 (23.3) 4 637 (33.9) 1 1274 (35.4) 17 2290 (9.2)
Smoking (%) 6908 (8.6) 146 (3.1) 1 178 (9.5) 6 285 (7.9) 13 7957 (31.8)
Corticosteroids use (%) 923 (1.2) 98 (2.2) 164 34 (1.8) 6 387 (10.9) 62 25,034
Rheumatoid arthritis (%) 758 (1.0) 226 (4.8) 27 (1.5) 23 252 (7.1) 74 572 (2.3)
Parental fracture (%) 80,014 600 (16.8) 1098 164 (13.7) 686 424 (14.3) 646 25,034
At-risk drinking* (%) 80,014 182 (3.9) 6 52 (2.8) 27 102 (2.8) 1 25,034
Baseline falls§ (%) 80,014 984 (21.1) 298 (15.9) 6 1021 (28.3) 6 25,034
Secondary osteoporosis (%) 3352 (4.2) 4663 1880 3615 25,034
FRAX for MOF (SD) 5.1 (3.1) 9.5 (4.7) 1 13.1 (5.6) 18.7 (9.5)
FRAX for hip fracture (SD) 0.7 (0.9) 3.8 (3.8) 1 7.0 (4.9) 6.4 (7.0)
FRAX-gSOS for MOF (SD) 5.4 (3.9) 10.1 (6.0) 6 13.7 (7.3) 19.3 (11.2) 38
FRAX-gSOS for hip fracture (SD) 0.9 (1.2) 4.2 (4.8) 6 7.7 (6.5) 7.0 (8.1) 38
FRAX-BMD for MOF (SD) 4.9 (2.6) 75,273 8.1 (4.4) 2 11.1 (6.3) 19 17.1 (9.5) 151
FRAX-BMD for hip fracture (SD) 0.7 (1.0) 75,273 2.5 (3.3) 2 5.3 (5.5) 19 5.0 (6.7) 151
Incident major osteoporotic fracture (incidence proportion) 1189 (1.5) 560 (12.0) 337 (17.9) 707 (20.6) 323 (1.3)
Incident hip fracture (incidence proportion) 209 (0.3) 273 (5.9) 129 (6.9) 556 (15.6) 67 (0.3)
*Though alcohol use is available in the UK Biobank and the CKB, no information regarding the frequency of drinking to determine at-risk drinking (≥ 3 drinks per day)




































gSOS is largely independent of clinical risk factors
gSOS demonstrated negligible correlations with FRAX
clinical risk factors examined, and this lack of correlation
was observed in each cohort separately (Additional file 1:
Table S2). However, there was a correlation between
gSOS and prior fracture (Pearson correlation ranged from
− 0.12 to − 0.07 across different European ancestry cohorts
and was − 0.05 in the CKB cohort). These findings suggest
that gSOS might be a predictor of incident fracture, inde-
pendent of FRAX clinical risk factors.
Extremes of gSOS have large differences in incidence of
major osteoporotic fracture and hip fracture
In all European ancestry cohorts, a lower gSOS, which
predicts a lower SOS, was associated with a higher
incidence of major osteoporotic and hip fractures
(Fig. 1a, b). For example, among individuals with a gSOS
below the first percentile (1%), 6.0% (95% CI 4.5–7.6%)
experienced an incident major osteoporotic fracture and
2.5% (95% CI 1.5–3.6%) experienced an incident hip
fracture. In contrast, the incidence was only 0.7% (95%
CI 0.2–1.4%) and 0.3% (95% CI 0–0.7%) for major osteo-
porotic fracture and hip fracture, respectively, among in-
dividuals with a gSOS above the 99th percentile. This
represents an 8.6-fold and 8.3-fold higher incidence of
major osteoporotic and hip fracture, respectively. Similar
or more pronounced risk stratifications were achieved in
all cohorts; the discrepancies were even larger among
older individuals in the MrOS US, the MrOS Sweden,
and the SOF cohorts (Additional file 1: Table S3).
Fig. 1 Higher incidence of a major osteoporotic fracture and b hip fracture is associated with lower gSOS. All 90,172 individuals from four
European ancestry cohorts were grouped into nine groups with respect to gSOS percentiles: ≤ 1%, 1–5%, 5–20%, 20–40%, 40–60%, 60–80%, 80–
95%, 95–99%, and > 99%. Diamonds denote observed incidence in each gSOS group with darker colors representing higher incidence. Vertical
lines denote corresponding binomial proportion CIs. Summaries of cohort-specific incidence in each gSOS group are provided in Additional file 1:
Table S2
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Overall, individuals who experienced incident major
osteoporotic fracture or hip fracture had lower gSOS
(Additional file 1: Fig. S2).
gSOS was more strongly associated with fracture risk
than most clinical risk factors in European populations
To compare the strength of gSOS as a predictor of frac-
ture to standard risk factors used clinically and in the
FRAX score, we chose a series of cut-points to binarize
gSOS while matching the frequency of each clinical risk
factor. For example, 24.2% of the population across the
four European ancestry cohorts reported falls. We there-
fore identified individuals in the lowest 25.0% of the dis-
tribution of gSOS. We then examined whether the
association between fracture and falls was stronger than
that between fracture and having a gSOS among the
25% lowest in the population.
After aligning prevalence rates of risk factors, binar-
ized gSOS indicators had a stronger association with the
odds of major osteoporotic fracture and hip fracture,
Fig. 2 gSOS is more strongly associated with fracture risk than most clinical risk factors. a Comparison of associations between incident major
osteoporotic fracture risk and risk factors. Different thresholds of gSOS were selected such that a similar proportion of the population would be
affected by one of the clinical risk factors. b Comparison of the predictive performance of gSOS (red) and clinical risk factors (blue) in identifying
individuals that experienced incident major osteoporotic fracture. c Comparison of associations between incident hip fracture risk and risk factors.
d Comparison of the predictive performance of gSOS (red) and clinical risk factors (blue) in identifying individuals that experienced incident hip
fracture. Comparison of each clinical risk factor AUROC to gSOS AUROC was based on DeLong’s test; p values are presented in b and d. All
association tests were based on logistic regression models, adjusted for age and sex in individuals from four European ancestry cohorts. Only
clinical risk factors available in all cohorts are presented in b and d, based on 12,359 individuals with complete data. 95% CIs of AUROC were
derived from 200 bootstrap replicates. Summaries of the cohort-specific predictive performance of all risk factors are provided in Additional file 1:
Table S4
Lu et al. Genome Medicine           (2021) 13:16 Page 8 of 15
than most of the other clinical risk factors, except for
prior fracture (Fig. 2a, c). For instance, 25.0% of the
population with the lowest gSOS had a 1.68-fold (95%
CI 1.47–1.89) increased odds of major osteoporotic frac-
ture and a 1.57-fold (95% CI 1.34–1.84) increased odds
of hip fracture, whereas falls affected 24.2% of the popu-
lation, but only increased the major osteoporotic frac-
ture risk by 1.24-fold (95% CI 1.08–1.42) and the hip
fracture risk by 1.20-fold (95% CI 1.02–1.41). We note,
however, that the 95% CIs of these risk factors over-
lapped to some degree. In addition, a continuous gSOS
exhibited moderately enhanced or similar predictive
power for incident fracture, as measured by the AUROC
(0.734 (95% CI 0.727–0.740) for incident major osteo-
porotic fracture; 0.798 (95% CI 0.791–0.805) for incident
hip fracture) as other clinically relevant risk factors (Fig. 2b,
d; Additional file 1: Table S4), except measured femoral
neck BMD. This enhanced performance was consistent
across all study cohorts (Additional file 1: Table S4).
Furthermore, gSOS provided a means of stratification
of cumulative risk of both incident major osteoporotic
fracture and hip fracture. In the MrOS and the SOF
Fig. 3 gSOS effectively stratifies cumulative fracture risk. a Lower gSOS is associated with a higher cumulative incidence of major osteoporotic
fracture. b Comparison of the age-dependent predictive performance of gSOS (red) and clinical risk factors (blue) in identifying individuals that
experienced incident major osteoporotic fracture. c Lower gSOS is associated with a higher cumulative incidence of hip fracture. d Comparison
of the age-dependent predictive performance of gSOS (red) and clinical risk factors (blue) in identifying individuals that experienced incident hip
fracture. All association tests were based on 4663 men from the MrOS US and 3615 women from the SOF cohorts using Cox proportional hazard
models adjusted for sex. Only clinical risk factors available in both cohorts are presented. CIs of C-index were derived from 200
bootstrap replicates
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cohorts, substantial stratification in cumulative incidence
of fracture was observed especially among individuals
aged > 75 years (Fig. 3a, c), and this finding was consist-
ent if these cohorts were examined separately (Add-
itional file 1: Fig. S3).
The predictive performance of gSOS also surpassed
all clinical risk factors (Fig. 3b, d), except measured
femoral neck BMD and prior fracture, with a Cox-
model concordance index (C-index) of 0.623 (95% CI
0.603–0.642) for incident major osteoporotic fracture
and 0.672 (95% CI 0.650–0.695) for incident hip frac-
ture. We note that the C-index for prior fracture was
0.619 (95% CI 0.600–0.637) for incident major osteo-
porotic fracture and 0.669 (95% C: 0.647–0.691) for
incident hip fracture. Both indices were similar to
those of gSOS.
gSOS improved predictive performance when combined
with FRAX clinical risk factors in European populations
We found that combining gSOS with the clinical risk
factor-based FRAX (FRAX-CRF) score in all four Euro-
pean ancestry cohorts significantly improved the risk
prediction for both incident major osteoporotic fracture
and hip fracture (likelihood ratio test p values < 0.05;
Table 2), without largely modifying the effect size of the
FRAX-CRF score. Interestingly, combining gSOS with
measured femoral neck BMD or a clinical risk factor and
BMD-based FRAX (FRAX-BMD) also significantly
Table 2 gSOS is associated with fracture in addition to FRAX-CRF and FRAX-BMD. Odds ratios associated with risk predictors of
interest were based on logistic regression
Cohort UK Biobank test dataset
(N = 4717)*
MrOS US (N = 4663) MrOS Sweden
(N = 1880)




Fracture ~ FRAX-CRF FRAX-CRF§ 1.15 (1.10–1.20) 1.06 (1.04–1.08) 1.04 (1.02–1.06) 1.04 (1.03–1.05)
Fracture ~ FRAX-CRF + gSOS FRAX-CRF 1.14 (1.09–1.19) 1.06 (1.04–1.08) 1.04 (1.02–1.06) 1.04 (1.03–1.05)
gSOS 1.41 (1.18–1.69) 1.36 (1.24–1.49) 1.39 (1.23–1.58) 1.30 (1.19–1.42)
Likelihood ratio test p value 1.4 × 10−4 3.1 × 10−11 6.9 × 10−8 2.5 × 10−9
Fracture ~ age + sex + BMD BMD¶ 1.66 (1.35–2.05) 1.79 (1.64–1.97) 1.86 (1.62–2.15) 2.02 (1.80–2.27)
Fracture ~ age + sex + BMD + gSOS BMD 1.53 (1.24–1.90) 1.72 (1.56–1.89) 1.79 (1.55–2.07) 1.93 (1.72–2.17)
gSOS 1.33 (1.11–1.59) 1.22 (1.11–1.34) 1.29 (1.14–1.47) 1.22 (1.11–1.33)
Likelihood ratio test p value 2.4 × 10−3 3.4 × 10−5 6.0 × 10−5 2.1 × 10−5
Fracture ~ FRAX-BMD FRAX-BMD§ 1.17 (1.12–1.22) 1.10 (1.08–1.12) 1.07 (1.05–1.08) 1.06 (1.05–1.07)
Fracture ~ FRAX-BMD + gSOS FRAX-BMD 1.16 (1.11–1.21) 1.09 (1.08–1.11) 1.06 (1.04–1.08) 1.06 (1.05–1.07)
gSOS 1.34 (1.12–1.60) 1.28 (1.17–1.40) 1.33 (1.18–1.51) 1.22 (1.12–1.34)
Likelihood ratio test p value 1.5 × 10−3 1.5 × 10−7 4.5 × 10−6 1.1 × 10−5
Hip fracture
Fracture ~ FRAX-CRF FRAX-CRF 1.06 (1.04–1.09) 1.02 (0.98–1.05) 1.05 (1.04–1.06)
Fracture ~ FRAX-CRF + gSOS FRAX-CRF 1.06 (1.04–1.09) 1.02 (0.98–1.05) 1.05 (1.04–1.06)
gSOS 1.36 (1.20–1.54) 1.25 (1.04–1.50) 1.31 (1.19–1.44)
Likelihood ratio test p value 1.1 × 10−6 1.6 × 10−2 4.2 × 10−8
Fracture ~ age + sex + BMD BMD 2.08 (1.83–2.38) 2.45 (1.96–3.08) 2.04 (1.80–2.32)
Fracture ~ age + sex + BMD + gSOS BMD 2.01 (1.76–2.31) 2.41 (1.92–3.04) 1.95 (1.72–2.22)
gSOS 1.17 (1.03–1.33) 1.11 (0.92–1.34) 1.20 (1.08–1.32)
Likelihood ratio test p value 1.7 × 10−2 2.7 × 10−1 3.7 × 10−4
Fracture ~ FRAX-BMD FRAX-BMD 1.10 (1.08–1.13) 1.06 (1.04–1.09) 1.07 (1.05–1.08)
Fracture ~ FRAX-BMD + gSOS FRAX-BMD 1.10 (1.07–1.12) 1.06 (1.04–1.09) 1.06 (1.05–1.08)
gSOS 1.31 (1.15–1.48) 1.20 (1.00–1.44) 1.25 (1.13–1.37)
Likelihood ratio test p value 3.0 × 10−5 5.3 × 10−2 1.1 × 10−5
*Only 4717 individuals in the UK Biobank had measured femoral neck BMD and were included; 125 individuals experienced incident major osteoporotic fracture;
only one individual experienced incident hip fracture; thus, model comparison was not conducted
§Based on one unit (percent of 10-year fracture probability) increase in FRAX-CRF or FRAX-BMD
¶Based on one standard deviation decrease in measured femoral neck BMD
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enhanced risk prediction (likelihood ratio test p values <
0.05; Table 2).
We therefore developed a combined score including
gSOS and the FRAX score with clinical risk factors
(FRAX-gSOS; the “Methods” section). Although the
FRAX-BMD score remained the best predictor for both
major osteoporotic fracture (AUROC 0.756 (95% CI
0.749–0.762); AUPRC 0.275 (95% CI 0.268–0.285); C-
index 0.689 (95% CI 0.670–0.707)) and hip fracture
(AUROC 0.806 (95% CI 0.799–0.813); AUPRC 0.211
(95% CI 0.203–0.222); C-index 0.722 (95% CI 0.701–
0.742)), the FRAX-gSOS score had a modestly improved
predictive performance compared to the FRAX-CRF
score. Specifically, the FRAX-gSOS offered a higher true
positive rate at most given false positive rates, as well as
greater positive predictive value at most levels of sensi-
tivity, as indicated by the ROCs and PRCs (Fig. 4a, b, d,
e) although the magnitude of these differences was not
large. Correspondingly, the FRAX-gSOS score had a
modestly higher AUROC (0.741 (95% CI 0.734–0.737)
vs. 0.733 (95% CI 0.727–0.740), DeLong’s test p value =
1.9 × 10−2, for major osteoporotic fracture; 0.791 (95%
CI 0.784–0.797) vs. 0.787 (95% CI 0.780–0.793),
DeLong’s test p value = 0.23, for hip fracture), AUPRC
(0.250 (95% CI 0.242–0.258) vs. 0.233 (95% CI 0.227–
0.240) for major osteoporotic fracture; 0.185 (95% CI
0.178–0.194) vs. 0.172 (95% CI 0.166–0.180) for hip frac-
ture), and C-index (0.660 (95% CI 0.641–0.679) vs. 0.647
(95% CI 0.603–0.642) for major osteoporotic fracture;
0.682 (95% CI 0.660–0.704) vs. 0.666 (95% CI 0.644–
0.688) for hip fracture) than the FRAX-CRF score
(Fig. 4c, f).
In all four study cohorts, including gSOS in the FRAX
score generally increased the predicted probability of
Fig. 4 Comparison of the predictive performance of FRAX-CRF, FRAX-BMD, and FRAX-gSOS. a Receiver operating characteristic curves, b
precision-recall curves, and c summaries of the predictive performance of FRAX-based scores for predicting incident major osteoporotic fracture
risk. d Receiver operating characteristic curves, e precision-recall curves, and f summaries of the predictive performance of FRAX-based scores for
predicting incident hip fracture risk. AUROC and AUPRC were derived based on all 90,172 individuals from four cohorts. C-indices were derived
based on 4663 men from the MrOS US and 3615 women from the SOF cohorts using Cox proportional hazard models. All CIs were derived from
200 bootstrap replicates
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future fracture (Table 1), and more individuals were
classified as having higher major osteoporotic fracture
risk or hip fracture risk (Table 3, Additional file 1: Table
S5, and Additional file 1: Table S6). Furthermore, the
positive overall NRIs and IDIs suggested that this could
refine the risk screening (Table 3, Additional file 1:
Table S5, and Additional file 1: Table S6). For instance,
adding gSOS to the FRAX score refined the prediction
of major osteoporotic fracture risk with NRIs being
0.028 in the UK Biobank test dataset, 0.043 in the MrOS
US, 0.072 in the MrOS Sweden, and 0.024 in the SOF.
Improvements were also observed for re-classifying the
risk of hip fracture across all cohorts, with the exception
that, in the SOF cohort, FRAX-gSOS did not better
identify individuals at higher risk of hip fracture.
gSOS was associated with fracture risk at an attenuated
magnitude in an Asian population
A standard deviation decrease in gSOS was associated
with an increased odds of incident major osteoporotic
fracture in the UK Biobank, MrOS US, MrOS Sweden,
and SOF cohorts, ranging from 1.35 to 1.46 (Table 4). In
contrast, this decrease was associated with an attenuated
1.26-fold (95% CI 1.13–1.41) increased odds of incident
major osteoporotic fracture in the CKB cohort (Table 4).
Similarly, the association between a decrease in gSOS
and increase in incident hip fracture risk was also
slightly smaller in the CKB cohort, compared to those of
European ancestry (Table 4). This attenuation was not
modified by consideration of other risk factors (Table 4).
Discussion
Here, we generated a genome-wide polygenic risk score
for SOS, gSOS, from 341,449 individuals of European
ancestry and tested its performance characteristics for
predicting incident fracture in four European ancestry
cohorts comprising 90,172 individuals. While the source
population, the UK Biobank, which we used to develop
the polygenic risk score was not completely representa-
tive of a general population, we provide evidence that
gSOS, particularly at its extremes, is consistently
associated with risk of major osteoporotic and hip frac-
ture across multiple cohorts. Since gSOS does not cap-
ture all variance in measured BMD, it does not predict
fracture as accurately as the latter. However, gSOS has a
moderately higher associated odds of incident fracture
and a better predictive performance of incident fracture
risk than many traditional clinical risk factors. Indeed,
gSOS remained associated with incident fracture, even
after accounting for FRAX-CRF and FRAX-BMD. Fur-
ther, gSOS improved the clinical risk factor-based FRAX
score and resulted in modestly better risk stratification
for fracture.
By summarizing genetic predisposition conferred by
polymorphisms throughout the human genome, poly-
genic risk scores can now be tested for their ability to
predict common disease outcomes and their risk factors.
For instance, a polygenic risk score for breast cancer is
able to identify 10% of the population having a 32.6%
lifetime risk [47]. These polygenic risk scores can be
generated from one single investment in genome-wide
genotyping, the cost of which is now approximately $40
USD in a research context [48]. However, sample collec-
tion, DNA extraction, and technical support will also
incur additional costs. Though technologies for measur-
ing BMD, such as DXA scan, are well-developed and of
clinical utility [49], their cost and restricted accessibility
currently limits risk screening to only a proportion of
the population. Therefore, as polygenic risk scores con-
tinue to improve, with larger sample sizes providing bet-
ter estimates of SOS and BMD, such polygenic risk
scores may find a clinical utility to assist in fracture
prediction.
Using FRAX-gSOS modestly improved predictive
performance over a FRAX-CRF score. Specifically, a
small proportion of the population at high fracture
risk were correctly re-classified using FRAX-gSOS.
While FRAX-gSOS does not perform as well as
FRAX-BMD, given the low incremental cost of gener-
ating gSOS in individuals already genome-wide geno-
typed, FRAX-gSOS may improve risk prediction in
the proportion of the population for which BMD is
Table 3 Net reclassification improvement of fracture risk prediction using FRAX-gSOS
Cohort UKB* US§ SWE¶ SOF† UKB US SWE SOF
Major osteoporotic fracture Hip fracture
















































*The UK Biobank test dataset (N = 80,014)
§The MrOS US cohort (N = 4663)
¶The MrOS Sweden cohort (N = 1880)
†The SOF cohort (N = 3615)
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not measured. As sample sizes increase for genomic
studies, we expect that this predictive ability will fur-
ther improve. Besides, already gSOS provides informa-
tion above FRAX-BMD (Table 2), in terms of fracture
prediction.
Our study highlights several directions for future
studies. First, further improved polygenic risk scores
for BMD, in addition to SOS, may be pursued, since
BMD is a well-used metric of fracture risk that is in-
corporated into the FRAX algorithm [6, 50]. It should
be noted that genetic risk scores for BMD based on
polymorphisms affecting several pivotal BMD genes
have already been developed and shown to be able to
predict fracture risk from different perspectives [16,
17, 21]. However, in order to generate more accurate
genome-wide polygenic risk scores that could possibly
capture a larger proportion of total variance in BMD,
very large sample sizes of genome-wide genotyped in-
dividuals are required. Such resources do not cur-
rently exist for BMD. We anticipate this will improve
as more individuals are genome-wide genotyped with
BMD measures. Second, gSOS was developed among
white British individuals and the cohorts employed in
this study include predominantly individuals of Euro-
pean ancestry. As has been widely noted, when a
polygenic risk score is applied to populations of dif-
ferent ancestries, its predictive performance may vary,
sometimes to a large extent [51]. For instance, genetic
risk factors for osteoporotic fracture and BMD char-
acterized in European populations do not improve the
prediction of fracture risk in a Chinese population
[52]. Here, although gSOS was still significantly asso-
ciated with both incident major osteoporotic fracture
risk and hip fracture risk in the CKB cohort, the
magnitude of the association was attenuated. There-
fore, we think that gSOS should not be directly ap-
plied to populations with a non-European ancestry,
especially since a large number of SNPs in gSOS were
not present in the targeted population, due to differ-
ent imputation reference panels and, potentially,
changes in minor allele frequencies. However, we ex-
pect that upcoming studies developing population-
specific polygenic risk scores, which might properly
model linkage disequilibrium, minor allele frequencies,
population-specific effect sizes, and heritability [53],
will be able to address this important issue. Lastly, it
should be noted that gSOS yielded predictive and dis-
criminative power while being independent of most
fracture risk factors. While we endeavored to combine
gSOS and other risk factors through FRAX-gSOS for
improved prediction, more rigorous approaches may
warrant further research. Meanwhile, as has been
done for the FRAX clinical risk score, absolute risks
of fracture associated with FRAX-gSOS should be cal-
ibrated in a population-specific manner, accounting
for national differences in fracture rates.
Conclusions
In conclusion, we generated and validated a polygenic
risk score for SOS which is consistently associated
with the risk of fracture. While this score provides
Table 4 Odds ratios (OR) for the association between per standard deviation decrease in gSOS and increased odds of incident
fracture
OR (95% CI)* p value OR (95% CI), adjusted for RFs§ p value, adjusted for RFs
UK Biobank test dataset (N = 80,014)
Major osteoporotic fracture 1.46 (1.38–1.55) 1.1 × 10−37 1.42 (1.34–1.51) 1.4 × 10−32
Hip fracture 1.37 (1.19–1.57) 6.3 × 10−6 1.34 (1.16–1.53) 3.7 × 10−5
MrOS US (N = 4663)
Major osteoporotic fracture 1.38 (1.26–1.51) 2.2 × 10−12 1.31 (1.17–1.45) 1.1 × 10−6
Hip fracture 1.37 (1.21–1.56) 5.5 × 10−7 1.33 (1.15–1.55) 1.4 × 10−4
MrOS Sweden (N = 1880)
Major osteoporotic fracture 1.45 (1.28–1.65) 5.3 × 10−9 1.38 (1.17–1.63) 1.3 × 10−4
Hip fracture 1.31 (1.08–1.58) 5.0 × 10−3 1.35 (1.05–1.72) 1.8 × 10−2
SOF (N = 3615)
Major osteoporotic fracture 1.35 (1.24–1.47) 1.0 × 10−11 1.34 (1.21–1.48) 7.3 × 10−9
Hip fracture 1.31 (1.19–1.43) 1.4 × 10−8 1.32 (1.19–1.47) 4.1 × 10−7
CKB (N = 25,034)
Major osteoporotic fracture 1.26 (1.13–1.41) 5.3 × 10−5 1.22 (1.09–1.36) 6.8 × 10−4
Hip fracture 1.25 (0.98–1.60) 7.1 × 10−2 1.21 (0.94–1.54) 0.14
*Derived from logistic regression models adjusted for age and sex
§Derived from logistic regression models adjusted for age, sex and other available risk factors (RFs) listed in Table 1
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modestly better fracture risk discrimination than
many clinical risk factors, it does not perform as well
as BMD. However, gSOS should be explored as a tool
to provide better risk stratification to identify individ-
uals at high risk of fracture, particularly considering
that polygenic risk scores can be generated for mul-
tiple diseases from one single investment in genome-
wide genotyping.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13073-021-00838-6.
Additional file 1: Fig. S1: Distribution of discrepancies in minor allele
frequencies of SNPs between the China Kadoorie Biobank and the UK
Biobank; Fig. S2: Distribution of standardized gSOS among 90,172
individuals of European ancestry; Fig. S3: Cumulative incidence of major
osteoporotic fracture in (A) the MrOS US cohort and (B) the SOF cohort,
and cumulative incidence of hip fracture in (C) the MrOS US cohort and
(D) the SOF cohort; Table S1. Summary of model training and selection
in the UK Biobank; Table S2. Summary of Pearson correlation between
gSOS and clinical risk factors; Table S3. Summary of incidence of
osteoporotic fracture; Table S4. Summary of predictive power of gSOS
and clinical risk factors; Table S5. Details of net reclassification
improvement of major osteoporotic fracture risk prediction using FRAX-
gSOS; Table S6. Details of net reclassification improvement of hip frac-
ture risk prediction using FRAX-gSOS.
Abbreviations
AUPRC: Area under the precision-recall curve; AUROC: Area under the
receiver operating characteristic curve; BMD: Bone mineral density;
CI: Confidence interval; CKB: China Kadoorie Biobank; CRF: Clinical risk factor;
DXA: Dual-energy X-ray absorptiometry; FRAX: Fracture Risk Assessment Tool;
gSOS: Genomic speed of sound; HRC: Haplotype Reference Consortium;
IDI: Integrated discrimination index; LASSO: Least absolute shrinkage and
selection operator; MrOS Sweden: Sweden-based Osteoporotic Fractures in
Men Study; MrOS US: United States-based Osteoporotic Fractures in Men
Study; NRI: Net reclassification index; OR: Odds ratio; SNP: Single nucleotide
polymorphism; SOF: Study of Osteoporotic Fractures; SOS: Speed of sound
Acknowledgements
This study was enabled in part by support provided by Calcul Québec
(https://www.calculquebec.ca/) and Compute Canada (https://www.
computecanada.ca).
Authors’ contributions
J.B.R. initiated and supervised the study. T.L., V.F., J.K., M.N., and D.B.
performed the computational analyses. T.L., M.F., S.B., C.M.T.G., and J.B.R.
developed the methods. R.G.W., K.L., Z.C., L.L., M.K., D.M., E.O., E.V.M., J.A.K.,
W.D.L., R.J.C., and C.O. curated and managed the data. T.L. wrote the draft
manuscript. J.B.R., C.M.T.G., C.O., R.J.C., W.D.L., J.A.K., E.V.M., and E.O. revised the
manuscript critically. All authors read and approved the final manuscript.
Funding
The Richards Research Group is supported by the Canadian Institutes of
Health Research (CIHR: 365825; 409511), the Lady Davis Institute of the
Jewish General Hospital, the Canadian Foundation for Innovation, the NIH
Foundation, the Cancer Research UK, and the Fonds de Recherche Québec
Santé (FRQS). TL is supported by an FRQS Doctoral Training Fellowship and a
McGill University Faculty of Medicine Scholarship. DB is supported by the UK
National Institute of Health Research (NIHR) Oxford Biomedical Research
Centre. JBR is supported by an FRQS Clinical Research Scholarship. These
funding agencies had no role in the design, implementation, or
interpretation of this study. The views expressed are those of the authors
and not necessarily those of the National Health Service, the NIHR, or the UK
Department of Health and Social Care.
Availability of data and materials
Data that support the findings of this study are available from the UK
Biobank [25], the MrOS US cohort [26], the MrOS Sweden cohort [27], the
SOF cohort [28, 29], and the China Kadoorie Biobank [30], but restrictions
apply to the availability of these data, which were used under license for the
current study, and so are not publicly available. Data are however available
upon successful project applications to respective research committees.
gSOS has been deposited on the PGS catalog (https://www.pgscatalog.org/
score/PGS000657/).
Ethics approval and consent to participate
This research was approved by the UK Biobank, the MrOS US cohort, the
MrOS Sweden cohort, the SOF cohort, and the China Kadoorie Biobank
research committees. Specific institutional review board approval was not
required for this research. This research has been conducted using the UK




The authors declare that they have no competing interests.
Author details
1Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research,
Jewish General Hospital, Room H-413, 3755 Chemin de la
Côte-Sainte-Catherine, Montreal, Quebec H3T 1E2, Canada. 2Quantitative Life
Sciences Program, McGill University, Montreal, Canada. 3Centre for Bone and
Arthritis Research, Department of Internal Medicine and Clinical Nutrition,
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden. 4Bioinformatics Core Facility, Sahlgrenska Academy,
University of Gothenburg, Gothenburg, Sweden. 5Clinical Trial Service Unit
and Epidemiological Studies Unit, Nuffield Department of Population Health,
University of Oxford, Oxford, UK. 6National Institute for Health Research
Oxford Biomedical Research Centre, Oxford University Hospitals NHS
Foundation Trust, Oxford, UK. 7Department of Epidemiology, Biostatistics and
Occupational Health, McGill University, Montreal, Canada. 8Department of
Diagnostic Radiology, McGill University, Montreal, Canada. 9MRC Population
Health Research Unit, University of Oxford, Oxford, UK. 10School of Public
Health, Peking University Health Science Centre, Beijing, China. 11Clinical and
Molecular Osteoporosis Research Unit, Department of Orthopedics and
Clinical Sciences, Lund University, Lund, Sweden. 12Skåne University Hospital,
Malmö, Sweden. 13Bone & Mineral Unit, Oregon Health & Science University,
Portland, USA. 14Department of Medicine, Oregon Health & Science
University, Portland, USA. 15Mellanby Centre for Bone Research, Centre for
Integrated Research in Musculoskeletal Ageing, University of Sheffield,
Sheffield, UK. 16Centre for Metabolic Bone Diseases, University of Sheffield,
Sheffield, UK. 17Mary Mackillop Institute for Health Research, Australian
Catholic University, Melbourne, Australia. 18Department of Medicine,
University of Manitoba, Winnipeg, Canada. 19Department of Drug Treatment,
Sahlgrenska University Hospital, Gothenburg, Sweden. 20Department of
Human Genetics, McGill University, Montreal, Canada. 21Gerald Bronfman
Department of Oncology, McGill University, Montreal, Canada. 22Department
of Twin Research and Genetic Epidemiology, King’s College London, London,
UK.
Received: 29 July 2020 Accepted: 22 January 2021
References
1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet.
2002;359(9321):1929–36.
2. Kanis JA, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos
Int. 2000;11(8):669–74.
3. Gu Q, et al. Surgery for hip fracture yields societal benefits that exceed the
direct medical costs. Clin Orthop Relat Res. 2014;472(11):3536–46.
4. McCloskey EV, et al. Predictive ability of heel quantitative ultrasound for
incident fractures: an individual-level meta-analysis. Osteoporos Int. 2015;
26(7):1979–87.
5. Kanis JA, Johnell O. Requirements for DXA for the management of
osteoporosis in Europe. Osteoporos Int. 2005;16(3):229–38.
Lu et al. Genome Medicine           (2021) 13:16 Page 14 of 15
6. Kanis JA, et al. FRAX and the assessment of fracture probability in men and
women from the UK. Osteoporos Int. 2008;19(4):385–97.
7. Compston J, et al. UK clinical guideline for the prevention and treatment of
osteoporosis. Arch Osteoporos. 2017;12(1):43.
8. Force USPST, et al. Screening for osteoporosis to prevent fractures: US
Preventive Services Task Force Recommendation Statement. JAMA. 2018;
319(24):2521–31.
9. Lentle B, et al. Osteoporosis Canada 2010 guidelines for the assessment of
fracture risk. Can Assoc Radiol J. 2011;62(4):243–50.
10. Kanis JA, et al. A systematic review of intervention thresholds based on
FRAX: a report prepared for the National Osteoporosis Guideline Group and
the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.
11. Mars N, et al. Polygenic and clinical risk scores and their impact on age at
onset and prediction of cardiometabolic diseases and common cancers. Nat
Med. 2020;26(4):549–57.
12. Khera AV, et al. Genome-wide polygenic scores for common diseases
identify individuals with risk equivalent to monogenic mutations. Nat Genet.
2018;50(9):1219–24.
13. Arden NK, et al. The heritability of bone mineral density, ultrasound of the
calcaneus and hip axis length: a study of postmenopausal twins. J Bone
Miner Res. 1996;11(4):530–4.
14. Morris JA, et al. An atlas of genetic influences on osteoporosis in humans
and mice. Nat Genet. 2019;51(2):258–66.
15. Trajanoska K, et al. Assessment of the genetic and clinical determinants of
fracture risk: genome wide association and mendelian randomisation study.
BMJ. 2018;362:k3225.
16. Lee SH, et al. Multiple gene polymorphisms can improve prediction of
nonvertebral fracture in postmenopausal women. J Bone Miner Res. 2013;
28(10):2156–64.
17. Ho-Le TP, et al. Prediction of bone mineral density and fragility fracture by
genetic profiling. J Bone Miner Res. 2017;32(2):285–93.
18. Mitchell JA, et al. Genetic risk scores implicated in adult bone fragility
associate with pediatric bone density. J Bone Miner Res. 2016;31(4):789–95.
19. Estrada K, et al. Genome-wide meta-analysis identifies 56 bone mineral
density loci and reveals 14 loci associated with risk of fracture. Nat Genet.
2012;44(5):491–501.
20. Zhou H, et al. Genetic risk score based on the prevalence of vertebral
fracture in Japanese women with osteoporosis. Bone Rep. 2016;5:168–72.
21. Nethander M, et al. BMD-related genetic risk scores predict site-specific
fractures as well as trabecular and cortical bone microstructure. J Clin
Endocrinol Metab. 2020;105(4):e1344-57.
22. Eriksson J, et al. Limited clinical utility of a genetic risk score for the
prediction of fracture risk in elderly subjects. J Bone Miner Res. 2015;30(1):
184–94.
23. Forgetta V, et al. Development of a polygenic risk score to improve
screening for fracture risk: a genetic risk prediction study. PLoS Med. 2020;
17(7):e1003152.
24. Kim SK. Identification of 613 new loci associated with heel bone mineral
density and a polygenic risk score for bone mineral density, osteoporosis
and fracture. Plos One. 2018;13(7):e0200785.
25. Bycroft C, et al. The UK Biobank resource with deep phenotyping and
genomic data. Nature. 2018;562(7726):203–9.
26. Orwoll E, et al. Design and baseline characteristics of the osteoporotic
fractures in men (MrOS) study--a large observational study of the
determinants of fracture in older men. Contemp Clin Trials. 2005;26(5):569–
85.
27. Ohlsson C, et al. Low serum DHEAS predicts increased fracture risk in older
men: the MrOS Sweden Study. J Bone Miner Res. 2017;32(8):1607–14.
28. Schwartz AV, et al. Increased falling as a risk factor for fracture among older
women: the study of osteoporotic fractures. Am J Epidemiol. 2005;161(2):
180–5.
29. Cummings SR, et al. Appendicular bone density and age predict hip
fracture in women. The Study of Osteoporotic Fractures Research Group.
JAMA. 1990;263(5):665–8.
30. Chen Z, et al. China Kadoorie Biobank of 0.5 million people: survey
methods, baseline characteristics and long-term follow-up. Int J Epidemiol.
2011;40(6):1652–66.
31. Lu T, et al. Improved prediction of fracture risk leveraging a genome-wide
polygenic risk score. In: Journal of Bone and Mineral Research. Hoboken:
Wiley; 2020.
32. Fry A, et al. Comparison of sociodemographic and health-related
characteristics of UK Biobank participants with those of the general
population. Am J Epidemiol. 2017;186(9):1026–34.
33. McCarthy S, et al. A reference panel of 64,976 haplotypes for genotype
imputation. Nat Genet. 2016;48(10):1279–83.
34. Genomes Project C, et al. A global reference for human genetic variation.
Nature. 2015;526(7571):68–74.
35. Mellstrom D, et al. Free testosterone is an independent predictor of BMD
and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res.
2006;21(4):529–35.
36. Harvey NC, et al. Falls predict fractures independently of FRAX probability: a
meta-analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone
Miner Res. 2018;33(3):510–6.
37. Tibshirani R. Regression shrinkage and selection via the LASSO. J R Stat Soc
Ser B Methodol. 1996;58(1):267–88.
38. Robin X, et al. pROC: an open-source package for R and S+ to analyze and
compare ROC curves. BMC Bioinformatics. 2011;12:77.
39. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics.
1988;44(3):837–45.
40. Grau J, Grosse I, Keilwagen J. PRROC: computing and visualizing precision-
recall and receiver operating characteristic curves in R. Bioinformatics. 2015;
31(15):2595–7.
41. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and measuring
and reducing errors. Stat Med. 1996;15(4):361–87.
42. Harrell FE Jr, et al. Regression modelling strategies for improved prognostic
prediction. Stat Med. 1984;3(2):143–52.
43. Harrell FE Jr, Lee KL, Pollock BG. Regression models in clinical studies:
determining relationships between predictors and response. J Natl Cancer
Inst. 1988;80(15):1198–202.
44. Pencina MJ, et al. Evaluating the added predictive ability of a new marker:
from area under the ROC curve to reclassification and beyond. Stat Med.
2008;27(2):157–72 discussion 207-12.
45. Cosman F, et al. Clinician’s guide to prevention and treatment of
osteoporosis. Osteoporos Int. 2014;25(10):2359–81.
46. Kundu S, et al. PredictABEL: an R package for the assessment of risk
prediction models. Eur J Epidemiol. 2011;26(4):261–4.
47. Mavaddat N, et al. Polygenic risk scores for prediction of breast cancer and
breast cancer subtypes. Am J Hum Genet.
2019;104(1):21–34.
48. Shendure J, et al. DNA sequencing at 40: past, present and future. Nature.
2017;550(7676):345–53.
49. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis
and treatment of osteoporosis. Postgrad Med J.
2007;83(982):509–17.
50. Kanis JA, et al. Case finding for the management of osteoporosis with
FRAX--assessment and intervention thresholds for the UK. Osteoporos Int.
2008;19(10):1395–408.
51. Martin AR, et al. Clinical use of current polygenic risk scores may exacerbate
health disparities. Nat Genet. 2019;51(4):584–91.
52. Li YM, et al. Genetic risk factors identified in populations of European
descent do not improve the prediction of osteoporotic fracture and bone
mineral density in Chinese populations. Sci Rep. 2019;9(1):6086.
53. Wang Y, et al. Theoretical and empirical quantification of the accuracy of
polygenic scores in ancestry divergent populations. Nature
Communications. 2020;11(1):1–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lu et al. Genome Medicine           (2021) 13:16 Page 15 of 15
